Advertisements



Here"s Why Sarepta Therapeutics Jumped 17% in September

Lifting of a clinical hold continued the momentum......»»

Category: topSource: foxnewsOct 11th, 2018

A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy

Sarepta Therapeutics solidified its position as the leader in developing a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial released Thursday......»»

Category: topSource: barronsFeb 8th, 2019

June 21st Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsFeb 1st, 2019

Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher

Aratana Therapeutics (PETX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for .....»»

Category: worldSource: nytJan 22nd, 2019

April 18th Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsJan 14th, 2019

Sarepta Therapeutics: It"s Time To Buy The Duchenne Muscular Dystrophy And Gene Therapy Leader

Sarepta Therapeutics: It"s Time To Buy The Duchenne Muscular Dystrophy And Gene Therapy Leader.....»»

Category: topSource: seekingalphaJan 11th, 2019

Janney, Morgan Stanley Say Sarepta"s Gene Therapy Remains On Track

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market.  Latest Ratings for .....»»

Category: blogSource: benzingaJan 8th, 2019

Why Cara Therapeutics Is One of Wednesday’s Big Winners

Cara Therapeutics shares jumped on Wednesday after the firm announced a key update in its late-stage chronic kidney disease trial......»»

Category: blogSource: 247wallstJan 2nd, 2019

Meet the New Big Proteostasis Licensing Agreement

Proteostasis Therapeutics shares jumped on Monday after the company announced that a new licensing agreement with Genentech......»»

Category: blogSource: 247wallstDec 17th, 2018

Here"s Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since

The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December......»»

Category: topSource: foxnewsDec 11th, 2018

Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dolla.....»»

Category: topSource: insidermonkeyDec 8th, 2018

Why Arena Pharma Is Winning Big With Its New Collaboration

Arena Pharmaceuticals shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics......»»

Category: blogSource: 247wallstNov 15th, 2018

Sands Capital Management Buys Sarepta Therapeutics Inc, Edwards Lifesciences Corp, Abiomed Inc, ...

Related Stocks: EW, GLPG, FND, HDB, ZTS, SRPT, ABMD, HCM, BGNE, EB, BAP, CSCO,.....»»

Category: smallbizSource: nytNov 14th, 2018

Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?.....»»

Category: worldSource: nytNov 1st, 2018

Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018.....»»

Category: personnelSource: nytNov 1st, 2018

Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares

Related Stocks: SRPT,.....»»

Category: dealsSource: nytOct 30th, 2018

Sarepta, Lysogene Announce Exclusive License Agreement for LYS - SAF302, a Late- stage Gene Therapy for the Treatment of MPS IIIA; Grant of Option Rights to an Additional CNS Gene Therapy Candidate

Sarepta Therapeutics, Inc. read more.....»»

Category: blogSource: benzingaOct 26th, 2018

Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up

Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand. Sarepta Therapeutics, Inc. SRPT incurred an adjusted loss of 56 c.....»»

Category: smallbizSource: nytOct 25th, 2018

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2018 Results - Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaOct 25th, 2018

Sarepta Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides

Sarepta Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides.....»»

Category: topSource: seekingalphaOct 24th, 2018

Sarepta had $793.9M in cash, equivalents as of September 30

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 24th, 2018